Nausea

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

1100%

+ 36 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

13 programs

AprepitantPhase 4

MK0869, aprepitant / Duration of Treatment: 3 daysPhase 4

Standard POPhase 4

+8 more programs

Sharp TherapeuticsPA - Pittsburgh

13 programs

AprepitantPhase 4

MK0869, aprepitant / Duration of Treatment: 3 daysPhase 4

Standard POPhase 4

+8 more programs

ViiV HealthcareNC - Durham

1 program

OndansetronPhase 41 trial

Active Trials

NCT00429832Completed120Est. Nov 2005

HelsinnIreland - Dublin

1 program

Fosaprepitant dimegluminePhase 31 trial

Active Trials

NCT01074697Completed246Est. Apr 2015

AstraZenecaCAMBRIDGE, United Kingdom

1 program

esomeprazolePhase 3Small Molecule1 trial

Active Trials

NCT00206440Terminated43Est. Feb 2012

Prevail TherapeuticsNY - New York

1 program

LY3537021Phase 21 trial

Active Trials

NCT07169851Recruiting204Est. Feb 2027

SandozAustria - Kundl

2 programs

Ondansetron HCl 24 mg TabletsPhase 11 trial

Active Trials

NCT00946387Completed26Est. Sep 2004

NCT00947128Completed26Est. Oct 2004

Merck & Co.RAHWAY, NJ

2 programs

Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)N/A1 trial

MK0869, aprepitant / Duration of Treatment: 3 daysPHASE_33 trials

Active Trials

NCT00514878Completed2,000Est. Nov 2008

NCT00090207Completed477Est. Sep 2004

NCT00092196Completed820Est. Dec 2004

+1 more trials

Nielsen BioSciencesCA - San Diego

1 program

Sevoflurane-remifentanil anaesthesiaN/A1 trial

Active Trials

NCT00452855Completed160Est. May 2005

TakedaTOKYO, Japan

1 program

OndansetronPHASE_21 trial

Active Trials

NCT02006056Completed30Est. Jun 2014

GSKLONDON, United Kingdom

1 program

OndansetronPHASE_4

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

Merck & Co.MK0869, aprepitant / Duration of Treatment: 3 days

ViiV HealthcareOndansetron

Merck & Co.MK0869, aprepitant / Duration of Treatment: 3 days

HelsinnFosaprepitant dimeglumine

AstraZenecaesomeprazole

Merck & Co.MK0869, aprepitant / Duration of Treatment: 3 days

Prevail TherapeuticsLY3537021

TakedaOndansetron

SandozOndansetron HCl 24 mg Tablets

Merck & Co.Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

Nielsen BioSciencesSevoflurane-remifentanil anaesthesia

Clinical Trials (12)

Total enrollment: 5,018 patients across 12 trials

NCT00090207 Merck & Co.MK0869, aprepitant / Duration of Treatment: 3 days

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

Start: Jan 2004Est. completion: Sep 2004477 patients

Phase 4Completed

NCT00429832 ViiV HealthcareOndansetron

A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department

Start: Oct 2003Est. completion: Nov 2005120 patients

Phase 4Completed

NCT00092183 Merck & Co.MK0869, aprepitant / Duration of Treatment: 3 days

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Start: Oct 2002Est. completion: Feb 2004866 patients

Phase 4Completed

NCT01074697 HelsinnFosaprepitant dimeglumine

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Start: Apr 2010Est. completion: Apr 2015246 patients

Phase 3Completed

NCT00206440 AstraZenecaesomeprazole

Nexium Study To Suppress Nausea During Chemotherapy

Start: Aug 2005Est. completion: Feb 201243 patients

Phase 3Terminated

NCT00092196 Merck & Co.MK0869, aprepitant / Duration of Treatment: 3 days

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Start: Dec 2002Est. completion: Dec 2004820 patients

Phase 3Completed

NCT07169851 Prevail TherapeuticsLY3537021

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Start: Nov 2025Est. completion: Feb 2027204 patients

Phase 2Recruiting

NCT02006056 TakedaOndansetron

Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting

Start: Nov 2013Est. completion: Jun 201430 patients

Phase 2Completed

NCT00947128 SandozOndansetron HCl 24 mg Tablets

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions

Start: Sep 2004Est. completion: Oct 200426 patients

Phase 1Completed

NCT00946387 SandozOndansetron HCl 24 mg Tablets

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions

Start: Sep 2004Est. completion: Sep 200426 patients

Phase 1Completed

NCT00514878 Merck & Co.Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

Start: Aug 2007Est. completion: Nov 20082,000 patients

N/ACompleted

NCT00452855 Nielsen BioSciencesSevoflurane-remifentanil anaesthesia

Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea

Start: Jan 2002Est. completion: May 2005160 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 5,018 patients

12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.